Products and Resources Catalog

    This webinar focuses on increasing knowledge among providers in the assessment and treatment of wounds as related to intravenous drug and xylazine use.     LEARNING OBJECTIVES: Explain opioid use disorder as a chronic illness. Increase level of comfort in the treatment and assessment of wound care as it relates to intravenous drug and Xylazine use. Share best practices for incorporating harm reduction philosophies and principles in the treatment of opioid use disorder (OUD).     TRAINERS:   Nicole Gastala, MD   Dr. Gastala is board certified in Family Medicine and Addiction Medicine. She graduated from Loyola Stritch School of Medicine and completed her Family Medicine residency at the University of Iowa. In her clinical role, she has developed and expanded MAR by mentoring new prescribers, precepting residents, and training clinicians within the Chicago and Illinois communities.  She has also focused on the development of a walk-in integrated behavioral health, addiction, and primary care program within her FQHC system. In January 2021, Dr Gastala joined the team at the Substance Use Prevention and Recovery Division of IDHS as the medical director.     Michael Huyck, NP   Michael Huyck is a Family Nurse Practitioner at the UIH Mile Square Health Center and adjunct clinical assistant professor with the University of Illinois College of Nursing. His clinical role at Mile Square is focused on integrative substance use disorder treatment and primary care. His clinical interests involve decreasing barriers to addiction care, piloting evidenced based interventions to address problems specific to populations with SUD, and training future nurses to care for those experiencing addiction. He provides a full range of SUD treatment including buprenorphine and methadone within his practice. His current projects include wound care and ultrasound guided phlebotomy for people who inject drugs.     The Great Lakes A/MH/PTTC is offering this training for individuals working in HHS Region 5: IL, IN, MI, MN, OH, WI. This training is being provided in response to a need identified by Region 5 stakeholders.

This FREE Virtual Learning Series is designed enhance education and training related to substance use disorders and to gain comprehensive knowledge and valuable insights into the world of addiction, focusing on four significant substances: alcohol, tobacco, opioids, and stimulants. This engaging and informative series has been designed to equip individuals, families, educators, and healthcare professionals with the tools they need to understand, prevent, and address substance abuse issues effectively. Whether you're seeking personal knowledge, professional development, or the tools to help someone in need, our Substance Abuse Virtual Learning Series offers a valuable opportunity to make informed choices and contribute to healthier, substance-free lives. Together, we can break the chains of addiction and create a brighter, healthier future for all. Join us in this transformative journey towards recovery and prevention. Module 1: Alcohol Use Disorder Screening and Treatment This module introduces Alcohol Use Disorder Screening and Treatment in the Latino population. Module 2: Tobacco Use Disorder Screening and Treatment This module introduces the Treatment of Tobacco Use Disorder in Latino Populations. Module 3: Opioid Use Disorder Screening and Treatment This module introduces the Screening and Treatment of Opioid Use Disorder in Latino Populations. Module 4: Stimulant Use Disorder Screening and Treatment This module introduces Screening and Treatment of Stimulant Use Disorder in Latino Populations.   Español Series de aprendizaje sobre el trastorno por consumo de sustancias Esta serie de aprendizaje virtual GRATIS está diseñada para mejorar la educación y la formación relacionadas con los trastornos por consumo de sustancias y para obtener conocimientos integrales y valiosos sobre el mundo de la adicción, centrándose en cuatro sustancias importantes: alcohol, tabaco, opioides y estimulantes. Esta serie atractiva e informativa ha sido diseñada para equipar a individuos, familias, educadores y profesionales de la salud con las herramientas que necesitan para entender, prevenir y abordar los problemas de abuso de sustancias de manera efectiva. Ya sea que esté buscando conocimiento personal, desarrollo profesional o las herramientas para ayudar a alguien necesitado, nuestra serie de aprendizaje virtual sobre abuso de sustancias ofrece una valiosa oportunidad para tomar decisiones informadas y contribuir a una vida más saludable y libre de sustancias. Juntos, podemos romper las cadenas de la adicción y crear un futuro más brillante y saludable para todos. Únase a nosotros en este viaje transformador hacia la recuperación y la prevención. Módulo 1: Detección y Tratamiento del Trastorno por Consumo de Alcohol . Este módulo presenta Detección y Tratamiento del Trastorno por consumo de Alcohol y Sustancias en la población Latina. Módulo 2: Detección y Tratamiento del Trastorno por el Uso del Tabaco Este módulo presenta el Tratamiento del Trastorno por Consumo de Tabaco en Poblaciones Latinas. Módulo 3: Detección y Tratamiento del Trastorno por el uso de opioides Este módulo presenta los Exámenes de detección y tratamiento del trastorno por consumo de opioides en poblaciones Latinas. Módulo 4: Detección y Tratamiento del Trastorno por el uso de Estimulantes Este módulo presenta Detección y tratamiento del trastorno por consumo de estimulantes en poblaciones Latinas.    

    Throughout the United States, an estimated 1-2 million older adults are in need of treatment for substance use disorders (SUDs). This presentation addresses evidence-based best practices for treating older adults with substance use disorder.     LEARNING OBJECTIVES: Identify commonly used drugs for older adults and the risks associated with these substances. Describe logistical differences in treating and responding to older adults with SUD. Present effective treatment strategies for treating older adults.     TRAINER: Randall Webber, MPH, CADC, has worked in the addiction field for the past 45+ years as a counselor, program director and trainer. He has provided training on street drug pharmacology, addiction science, counselor ethics, and substance abuse treatment strategies. Randall has authored or co-authored numerous publications and has held teaching positions at several colleges and universities. He also serves on the board of directors of the Illinois Association of Addiction Professionals     The Great Lakes A/MH/PTTC is offering this training for individuals working in HHS Region 5: IL, IN, MI, MN, OH, WI. This training is being provided in response to a need identified by Region 5 stakeholders.

  Treatment for Individuals who Use Stimulants TRUST A Protocol Using Empirically-Supported Behavioral Treatments for People with Stimulant Use Disorders     Purpose of the TRUST-MAIN Manual The authors of this manual have been involved in StimUD-related research, treatment, and training efforts for over 30 years. Over this period, the research on StimUD and its treatment has vastly increased and there is a great interest in better understanding StimUD and providing effective treatment for people who use cocaine and methamphetamine. We have produced this manual to promote the use of research-supported strategies for StimUD treatment. The manual attempts to combine a number of strategies into a framework that is appropriate for use by clinicians in settings where people with StimUD receive treatment. This manual is not intended to be a cookbook and the materials used and the framework for their use are not intended to be an inflexible, one-size-fits-all prescription. At the end of the manual, we list a variety of treatment materials (see Appendix) that can be added or substituted for the ones we are recommending. We provide the contents of this manual and the framework for combining these treatment materials as one example for how research-supported strategies can be combined into a structured treatment experience. The manual was developed at a time when CM with adequate incentives was considered impossible in the U.S. Hence, this manual was produced to offer a possible, albeit a non-evidence-based and certainly less effective alternative to CM. As evidence-based CM protocols using adequate incentives are increasingly being developed and implemented in the U.S., there is interest in having CM delivered within a framework of other evidence-based behavioral support. The use of the materials in the TRUST Manual to augment CM treatment is another possible use of the manual, either in the form of a 12-week framework, or as ad hoc behavioral support materials. The audience for the manual includes healthcare professionals who provide treatment services for individuals with StimUD. One category of these professionals who we particularly hope will benefit are therapists and other behavioral health clinicians who work in substance use disorder specialty care treatment programs. The manual has been written with this group in mind.   The manual intends to: Provide new information about the use and effects of cocaine and methamphetamine. Present several key clinical challenges that clinicians face when treating this population. Review the evidence-based treatment strategies for StimUD treatment. Discuss how motivational interviewing (MI) is central to the effective engagement of individuals in treatment and to assisting them with behavior change during treatment. Present how elements of community reinforcement approach (CRA) and cognitive behavioral therapy (CBT) can be used to assist individuals with StimUD to reduce/discontinue their drug use and prevent relapse. Describe a procedure for incorporating positive incentives into the treatment milieu and/or support the use of CM for the treatment of StimUD. Provide information and guidance for how physical exercise can benefit individuals who are attempting to reduce/discontinue their use of methamphetamine and cocaine. Describe a plan for providing continuing care to assist individuals to sustain the progress they have made in a structured treatment program. List an array of manuals and training resources for other research-supported substance use disorder treatment approaches.   For those working with people receiving care for Opioid Use Disorder, an adapted version is available Treatment for Individuals who Use Stimulants while on MOUD TRUST—MOUD THERAPIST MANUAL & PATIENT WORKBOOK       Purpose of the TRUST-MOUD Manual The TRUST MOUD Manual is intended to be used with patients who are struggling with stimulant (cocaine/amphetamine) use while in treatment for OUD with methadone, buprenorphine, or naltrexone. Working with patients presenting in MOUD treatment is a challenging, yet incredibly rewarding experience. While it is rewarding, it can also be frustrating. Stimulant use among these patients is common and many patients don’t see their use as problematic. In fact, for some patients who use stimulants sporadically, they may not need treatment. But certainly, for some patients on MOUD, cocaine/meth use is extremely detrimental to the effectiveness of their MOUD treatment and is a serious health problem. However, in many cases, regardless of the severity of use, the patients often don’t recognize their stimulant use as a problem, and they are not interested in intensive treatment. The materials in the TRUST MOUD Manual attempt to provide this patient population with a useful set of information in a format that they find acceptable. The materials adopt CRA, CBT, and MI content and present it in a clear and relevant form that addresses the challenges they face while in MOUD treatment. We try to avoid long, didactic, lecturing materials, but rather try to create accessible topics and examples. TRUST was developed with flexibility in mind to optimize patient engagement and retention. TRUST materials can be presented in 1:1 sessions and can be scheduled with patients or in on-going stimulant treatment groups. Topics can be presented in a sequence and frequency that lets therapists select content to meet patient needs. The 24 TRUST worksheets can be used in a flexible manner to be relevant and useful to patients. Consistency is important when using the TRUST Manual. Set and adhere to meeting days and times. Start and end sessions on time. If used in a group format, have some group participation guidelines. Adhering to a specific session format and timing will enhance patients’ understanding of the group/individual session process and will allow them to focus on acquisition of new material. Patients using stimulants will undoubtedly experience cognitive impairment as they participate in sessions and utilize the TRUST materials. Slowing down to allow patients to gather their thoughts and express themselves during group or individual sessions is important. In addition, using multi-media and repetition can be helpful for patients to grasp new concepts. Use of Motivational Interviewing as a fundamental style and interpersonal approach is essential to success when using TRUST materials. Ideally, TRUST session attendance should be paired with medication visit attendance to reduce the travel burden on patients. This is especially true in rural areas, where public transportation is non-existent, or when a patient has employment, education, or homemaking responsibilities. When possible, patients should have an opportunity to determine therapy visit days and times based upon their scheduling needs. Research has shown that aerobic exercise improves cognitive capacity, reduces depression and anxiety, and improves cardiac and pulmonary function for individuals with stimulant use disorder. Several of the TRUST worksheets discuss the benefits of exercise as part of a treatment effort to reducing stimulant use. Encouraging patients to exercise will also help them to manage emotional highs and lows and help them structure their day. Getting patients to exercise is often difficult and requires ongoing encouragement and support. The TRUST materials and their use with patients on MOUD should be used with a strong harm reduction foundation. The #1 priority for this group of patients is retention in treatment with MOUD. Participation in treatment activities with TRUST materials, when appropriate, should be encouraged, rewarded, and praised. In our opinion, requiring treatment attendance with TRUST materials, with a threat of MOUD discontinuation is never justified. In an era of lethal drugs including fentanyl, retention on MOUD is essential. Other harm reduction activities should be combined with TRUST materials. Access to safe injection supplies, ready access to naloxone and fentanyl test strips, and as new drugs emerge (e.g., xylazine), it is critical to provide new information and test strips as they become available. Many patients in MOUD treatment have multiple life challenges, including use of numerous drugs and alcohol, food insecurity, being unhoused, unemployment, as well as both mental health and physical health issues. To be successful, patients will need to be retained in treatment for a significant period of time, if not for a lifetime. These issues are not going to be resolved overnight, but rather through consistent and prolonged effort. We hope these materials can be useful to your work with patients on MOUD.   Authors Richard Rawson, PhD Richard A. Rawson, PhD, is Professor Emeritus at the UCLA Department of Psychiatry and a Research Professor at the Vermont Center for Behavior and Health at the University of Vermont. He received a Ph.D. in experimental psychology from the University of Vermont in 1974. Dr. Rawson conducted numerous clinical trials on pharmacological and psychosocial addiction treatment and extensive system evaluation activities in a number of states and countries. He has led addiction research and training projects for the United Nations, the World Health Organization, and the U.S. State Department, exporting science-based knowledge to many parts of the world. Dr. Rawson has published 3 books, 40 book chapters, and over 250 peer-reviewed articles and has, for almost 50 years, conducted workshops, paper presentations, and training sessions in many areas of the world.   Albert Hasson, MSW Albert L. Hasson received his MSW from UCLA and has worked in the field of addiction medicine as a researcher and a treatment provider since 1977. Mr. Hasson participated in the development of the evidence-based Matrix Model, a cognitive behavioral intervention for StimUD Treatment, and established the Matrix Institute on Addictions, Los Angeles opioid treatment program. Along with his administrative and clinical experience, Mr. Hasson has extensive experience in implementing and evaluating behavioral and pharmacologic interventions. He has served as a project director and trainer for the Pacific Southwest Addiction Technology Transfer Center at the UCLA Integrated Substance Abuse Programs.   Janice Stimson, PsyD Janice Stimson, PsyD, has worked in the field of addiction treatment since 1998. For 20 years she has worked at the Matrix Institute on Addictions in the role of Clinic Director, overseeing and managing the clinic, seeing clients and supervising staff. At the clinic private adolescent and adult treatment programs coexisted along-side national research studies. Dr. Stimson held key positions in those studies and was responsible for ensuring the success of fulfilling recruitment, training, supervision, and protocol requirements.   Michael McCann, MA Michael McCann, M.A., is one of the founders of the Matrix Institute on Addictions and creators of the Matrix Model. He has overseen the operation of Matrix clinics as well as the integration of many research projects within these sites. He has over 40 years of experience in substance use disorder treatment and research, and has authored or co-authored over 40 articles, books, and manuals. He has trained and lectured extensively on evidence-based behavioral interventions, pharmacologic treatments, methamphetamine dependence, opioid dependence, and on the implementation of evidence-based treatments into clinical practice   Acknowledgements The authors would like to acknowledge the assistance provided by Thomas E. Freese, PhD, Beth Rutkowski, MPH, Gloria Miele, PhD, and Valerie P Antonini, MPH. Christine Morgan provided invaluable support with the production of the manual, along with editing support from Victoria T. Norith and Benjamin Nguyen, MSW, CPH. The materials in this manual include content and worksheets from the Matrix Model Therapist Manual (SAMHSA, 2006); from the Community Reinforcement Approach, plus Vouchers Manual (NIDA, 2020).

The purpose of the listening sessions was to gather information from family members and loved ones of people with substance use challenges to better understand family members’ experiences supporting and seeking support for their loved one who is using substances; to ask what questions family members have about supporting their loved one who is using substances; to ask who or what is providing support for family members; and the unmet needs for support for family members. This report describes the process and findings of the first phase of this consultation process: listening sessions with family members and loved ones of people who use substances. This project is in collaboration with the African American Behavioral Health Center of Excellence and National Hispanic and Latino ATTC.

  SUD Keys to Education is a product for educators and clinical supervisors developed in 2022 by the Mountain Plains and Pacific Southwest Addiction Technology Transfer Centers (MPATTC and PSATTC). This product was developed to help community college/university faculty, as well as clinical supervisors and recovery support staff to have access to brief, science-based content with the goal of providing materials that can be easily infused into existing substance use disorder and related courses (e.g., social work, nursing, criminal justice, foundation of addiction courses, ethics, counseling courses, etc.) and for clinical and recovery staff use in in-service meetings. Individuals can select the specific content to infuse into existing curricula/materials depending on specific needs of their learners. Each slide in the slide decks contain notes to provide guidance on the topics along with references and handouts where appropriate. All of the stimulant-specific slide decks also have a video (MP4) of the content narrated by subject matter experts as an alternative way of presenting the materials. The main developers of the SUD Keys are: MPATTC, HHS Region 8: Cindy Juntenen, PhD, LP, Nancy Roget, MS, Trisha Dudkowski, BA, Kenneth Flanagan, PhD, Terra Hamblin, MA, Shannon McCarty, BS, Kim Miller, MS, Abby Roach-Moore, MSW, and Maridee Shogren, DNP PSATTC, HHS Region 9: Thomas E. Freese, PhD, and Beth Rutkowski, MPH.  

The Mountain Plains and Pacific Southwest ATTCs are pleased to offer a two-part recording focused on recovery support services as it relates to People With Stimulant Use Disorders (PWSUDs). In both recordings, a review of the current research is highlighted along with people with lived experience in stimulant use and recovery discussing the findings and relating it to their own experiences. The three panelists with lived experience, all currently work at well-established recovery community organizations (RCOs), one in Colorado- Advocates for Recovery and one in Utah- Utah Support Advocates for Recovery Awareness.  In Part 1 recovery support (e.g. definition of recovery, recovery capital, recovery benchmarks, etc.) and stimulant use (e.g., prevalence of use, impact on the brain, and craving) is discussed. While the Part 2 recording is focused on treatment and recovery services (e.g., treatment services, barriers to recovery, managing triggers and return to use, cessation triggers, 12 Step involvement, exercise, and involvement with RCOs). The overall goal of this two-part recording is to provide participants with a review of the latest science regarding stimulants within the context of people with lived experience highlighting the lessons learned from their recovery. Finally, promoting hope, community, and engagement as central/essential pieces to recovery from stimulant use disorders is a theme in both recordings with the panelists reinforcing that recovery is achievable for PWSUDs.   Recovery Support with Stimulant Use Disorders Part 1   Recovery Support with Stimulant Use Disorders Part 2        

While the first two installments of this webinar series focused on effective treatment strategies and models for addressing stimulant use disorders, this last installment featured three presenters discussing change management strategies for successfully implementing evidence-based practices (EBPs). Todd Molfenter, PhD, provided an overview on how implementation science informs successful uptake of EBPs. Bryan Hartzler, PhD, presented tips for community-based implementation of contingency management. Denna Vandersloot, MEd, shared lessons learned from implementation efforts involving the Matrix Model of treatment. Watch recording This is part 3 of a 3-part series on Stimulant Use Disorders sponsored by the Northwest and Great Lakes ATTCs. Find the complete series here.  Webinar category: Stimulants, Treatment - General

This 3-part webinar series was held in summer 2019 and sponsored by the Northwest ATTC and the Great Lakes ATTC. Part 1: Strategies to Address Cocaine and Methamphetamine Richard Rawson, PhD, UCLA School of Medicine, University of Vermont June 11, 2019 This presentation provided an overview of the current knowledge on the problem of stimulant (cocaine and methamphetamine) use in the U.S., including a review of the extent and geography of use, the clinical syndromes provided by acute and chronic use, a review of behavioral treatments with evidence of efficacy for the treatment of stimulant use disorders, and an overview of the current status of pharmacotherapy research on treatments for stimulant use disorders. Download slides | Watch recording Part 2: Provider Perspectives on Effective Strategies for Treating People with Stimulant Use Disorders Michelle Peavy, PhD, Dominick DePhilippis, PhD, Regina Fox, BS, CSAC July 18, 2019 This webinar featured a panel of providers presenting their experiences with effective treatment strategies and evidence-based practices for working with individuals with stimulant use disorders. Michelle Peavy, PhD, of Evergreen Treatment Services, addressed challenges and strategies of working with individuals with comorbid opioid use and stimulant use disorders Dominick DePhilippis, PhD, presented on use of contingency management with this population in the VA system Regina Fox, BS, CSAC discussed use of the Matrix Model of treatment in a community-based treatment organization Watch recording   Part 3: Implementing Evidence Based Practices to Address Stimulant Use Disorders Todd Molfenter, PhD, Bryan Hartzler, PhD, Denna Vandersloot, MEd August 15, 2019 While the first two installments of this webinar series focused on effective treatment strategies and models for addressing stimulant use disorders, this last installment featured three presenters discussing change management strategies for successfully implementing evidence-based practices (EBPs). Todd Molfenter, PhD, provided an overview on how implementation science informs successful uptake of EBPs. Bryan Hartzler, PhD, presented tips for community-based implementation of contingency management. Denna Vandersloot, MEd, shared lessons learned from implementation efforts involving the Matrix Model of treatment. Watch recording

Traumatic Brain Injury and Substance Use Disorder Toolkit now available!! Traumatic Brain Injury and Substance Use Disorders: Making the Connections merges the content on traumatic brain injury (TBI) and substance use disorders (SUD) to expand capacity to address both issues in treatment. The author, Dr. Carolyn Lemsky, is a board-certified neuropsychologist with over 25 years of experience working in rehabilitation settings in the U.S. and Canada. The toolkit provides valuable and practical information for advancing behavioral health providers’ capacity when serving persons who have brain injuries. Click here to download a free digital copy Click here to order a hard copy (shipping and handling fees apply)  This toolkit is a collaboration between the National Association of State Head Injury Administrators, Mountain Plains Addiction Technology Transfer Center (Mountain Plains ATTC), and the Mid-America Addiction Technology Transfer Center (Mid-America ATTC).

The Mid America Addiction Technology Transfer Center partnered with the Missouri Institute of Mental Health, the Opioid Response Network, and Saint Louis University, developed a new series in response to the rising needs of serving clients with Stimulant Use Disorder (StimUD). The purpose of the series is to provide education on treating clients with StimUD. This is the 3rd session in the series, Treating Stimulant Use Disorder: Doing What Works. Click here to watch the recording

The Mid America Addiction Technology Transfer Center partnered with the Missouri Institute of Mental Health, the Opioid Response Network, and Saint Louis University, developed a new series in response to the rising needs of serving clients with Stimulant Use Disorder (StimUD). The purpose of the series is to provide education on treating clients with StimUD. This is the 1st session in the series called Contingency Management Roundtable Click here to download the recording!  

The Mid America Addiction Technology Transfer Center partnered with the Missouri Institute of Mental Health, the Opioid Response Network, and Saint Louis University, developed a new series in response to the rising needs of serving clients with Stimulant Use Disorder (StimUD). The purpose of the series is to provide education on treating clients with StimUD. This is the 2nd session in the series, Harm Reduction for Stimulant Use Disorder. Click here to watch the recording

This webinar will review the pharmacological characteristics of stimulant medications and also medications that provide a stimulant effect and review which medications are most effective in enhancing natural recovery and improving fatigue and cognitive functioning in TBI survivors. A discussion regarding the similarity of ADHD symptoms to TBI symptoms will be presented. Frontal lobe and temporal lobe syndromes will be described, and specific medications will be reviewed that are likely to have a positive impact on the TBI survivor. Case studies will also be presented exemplifying the complexity of brain injury, cognitive impairment and effective use of medications.   Learning Objectives: Review the definitions, similarities and differences between Stimulant medications Describe the symptoms of TBI following or during rehabilitation Differentiate levels of TBI cognitive severity Understand the Psychopharmacology of Stimulant Medications Describe atypical stimulants, non-stimulants and antidepressants Understand the complexity of choosing a stimulant medication in a patient with TBI   Presenter Information Dr. Sparadeo began his career as the Director of the Mayor’s Task Force on Substance Abuse in the City of Providence, R.I. and he was also the Director of Substance Abuse Services for the Providence Mental Health Center at that same time. After creating a system of clinical services for the City of Providence he was appointed as CEO of Talbot House. Talbot House was the largest residential substance abuse treatment facility in New England. Dr. Sparadeo then completed his doctoral studies with a residency at the Boston V.A. Medical Center followed by a 2-year fellowship at Brown University and Rhode Island Hospital (RIH). The focus of his clinical training was neuropsychology and chronic pain. He completed his fellowship and was appointed to the Brown University School of Medicine faculty and the Rhode Island Hospital medical staff in the position of Director of Rehabilitation Psychology. Dr. Sparadeo trained numerous interns and fellows at Brown University. As Director of Rehabilitation Psychology, Dr. Sparadeo created the first comprehensive outpatient rehabilitation program for survivors of traumatic brain injury. After 8 years in his position at RIH Dr. Sparadeo was appointed National Director of Substance Abuse and TBI rehabilitation services at New Medico Health Systems in Boston, Massachusetts. He created inpatient substance abuse treatment programs in 8 rehabilitation facilities throughout the U.S. He returned to RIH and Brown University to become the director of the Concussion Care Center in the Emergency Department at RIH. He was also the chief clinical consultant to the Trauma Center and Stepdown Unit, and he was the co-director of the Interdisciplinary Spine Center in the Neurosurgery Department at RIH for 5 years before opening a private practice specializing in the neuropsychological assessment, pain assessment and pain management. He developed a specialized substance abuse treatment program for people with both TBI and substance abuse. Eventually, he developed a specialized treatment program for people with chronic pain and opiate addiction. Over the many years of his career Dr. Sparadeo has been a consultant to many agencies and healthcare programs throughout the U.S. He has also served on numerous boards of directors. He was the founder and president of the Brain Injury Association of Rhode Island. He was also the Chairman of the Governor’s Permanent Advisory Commission on TBI. He was also a member of the national committee on substance abuse and disability at SAMHSA in Washington, D.C. Most recently, Dr. Sparadeo has been a consultant and chief trainer on a federally funded grant at the Massachusetts Rehabilitation Commission. Dr. Sparadeo’s career has also included the publication of many scientific papers and book chapters, and he has been on the faculty of Salve Regina University graduate program in Rehabilitation Counseling where he teaches the Neuroscience of Substance Abuse and Mental Illness, Psychopharmacology for Counselors and the Neuroscience of Opioid Abuse.   Traumatic Injury & SUD: Implications of Stimulants on Traumatic Brain Injury

Talking To Change: A Motivational Interviewing Podcast, hosted by Glenn Hinds and Sebastian Kaplan, is a series of conversations exploring Motivational Interviewing (MI) and its influence on supporting individuals and groups as they make positive health and lifestyle changes. Talking to Change: An MI Podcast. Episode 44: MI and Social Support for Opioid and Stimulant Use Disorders, with Paul Delaney In part two of a pair of episodes on MI for opioid and stimulant use disorders, Glenn and Sebastian talked to Paul Delaney, clinical supervisor, therapist, adult educationalist, and trainer in Dublin, Ireland. Paul talked about working with people who misuse opioids and stimulants, how to avoid the premature focus trap, ways to support autonomy with someone who uses heroin, harm reduction, and MI and restorative justice.  Download the transcript (pdf)  

Talking To Change: A Motivational Interviewing Podcast, hosted by Glenn Hinds and Sebastian Kaplan, is a series of conversations exploring Motivational Interviewing (MI) and its influence on supporting individuals and groups as they make positive health and lifestyle changes, Talking to Change: An MI Podcast. Episode 42: MI for People with Opioid Use and Stimulant Use Disorders, with Roy Stein, MD In this episode (the first of two episodes about MI for opioid and stimulant use disorders), Glenn and Sebastian talk to Dr. Roy Stein, Clinical Professor of Psychiatry at University of North Carolina’s School of Medicine. Dr. Stein talks about ways to help people engaging in behavior that puts them at high risk for death, managing the “righting reflex” and reducing risk for burnout, the role of harm reduction for opioid use disorders, adaptations of MI for stimulant use disorders, medication treatment for substance use disorders, and more. Download transcript (pdf)

In this session, Larissa Mooney, MD, one of two PIs for the Greater Southern California Node of the NIDA Clinical Trials Network, discussed recent trends in co-occurring methamphetamine use and opioid use disorder (OUD), including overdose fatalities. Participants also learned about the treatment approaches to address this rising comorbidity. This webinar was sponsored by the Northwest and Pacific Southwest ATTCs and the Western States Node of the NIDA Clinical Trials Network. Download slides

The Kansas City Perinatal Recovery Collaborative (KCPRC) was formed in June 2018 by Mid-America ATTC in response to the growing impact of substance use on families in the bi-state metropolitan area.  The KCPRC works to develop, grow, and nurture a coordinated, multi-system network of services and programs to support pregnant and parenting mothers as they navigate the dual journey of parenting and recovery. KCPRC is a collective of professionals from child development, child welfare, housing, social services, health care, criminal justice, and substance use disorder treatment and recovery.  The group focuses on evidence-based ways care can be improved from pregnancy and throughout a woman’s continuum of care. 

Download the slides for the first session of the Traumatic Brain Injury & SUD Series: Brain Injury 101. This session will provide participants with an overview of brain injury including information on what brain injury is and the prevalence within the general population. The session will then describe brain injury in the context of high-risk populations such as intimate partner violence and criminal and juvenile justice. Finally, participants will gain an understanding for how to screen for brain injury and they will learn strategies for supporting individuals with brain injury within the addictions setting. Learning Objectives: Participants will be able to describe the prevalence of brain injury in the general and within special populations. Participants will learn about best practices for screening individuals for brain injury. Participants will learn how to support individuals identified with brain injury.   Presenter Information: Judy Dettmer has been working in the field of brain injury for 30 years. Ms. Dettmer is currently the Director for Strategic Partnerships and a Technical Assistance Lead for the Traumatic Brain Injury Technical Assistance and Resource Center at the National Association of State Head Injury Administrators. Ms. Dettmer has worked extensively with adults, children and family members of individuals with brain injury. She has provided direct and systems consultation to improve the lives of individuals with brain injury. Judy has also assisted with research efforts related to brain injury and has conducted countless presentations, classes and seminars on brain injury both in the state of Colorado and Nationally. Ms. Dettmer has provided technical assistance to numerous states including but not limited to; screening on brain injury, developing infrastructure within state systems such as departments of education, criminal justice, and in developing and managing advisory boards and councils. Ms. Dettmer is currently a co-facilitator for the National Collaborative on Children’s Brain Injury.

      This virtual presentation is sponsored by the Southeast ATTC Regional Center and will focus on central nervous stimulants and their impact on the user's brain, body, and behavior in Alabama, Georgia, Florida, Kentucky, Mississippi, Tennessee, North Carolina, South Carolina. Treatment providers, peer support communities, and community-based organizations in Region 4 are encouraged to register for free.     List at least three types of stimulants Describe the patterns and trends of stimulant use. Identify at least three impacts of stimulant use on people who use them. Summarize at least two specific treatment interventions that have proven effective in treating people with a stimulant use disorder.   .........................................   James E. Campbell, LPC, LAC, MAC, CACII has worked professionally in the human services field for over twenty-five years in a wide range of clinical settings, currently serving as the Training and Technical Assistance Manager for Southeast Addiction Technology Transfer Center.  His passion is helping individuals and families heal and build on the strengths they possess.  He’s a member of both NAADAC and ACA and is a past president of APSC/SCAADAC.  James is a nationally recognized, author and speaker.  

BHMEDS-R3 App The BHMEDS-R3 app is designed as a quick reference for non-prescriber behavioral health professionals and consumers who need general knowledge about medications prescribed for behavioral health conditions. The language has been modified to increase readability for a larger audience and, in keeping with the goal of continuously updating the app content, new medications are added after FDA approval. Download the FREE app using the QR codes below. Use the BHMEDS-R3 app for the following: Browse through different types of behavioral health medications Click a medication category icon to learn more details, including brand and generic names Use drop-down navigation menus to learn more about medications’ purpose, dose and frequency, side effects, emergency conditions, misuse potential, and cautions. Access provider tools and other free medication resources   BHMEDS-R3 Behavioral Health Medications Originally developed as a companion piece to the Mid-America ATTC curriculum, A Collaborative Response: Addressing the Needs of Consumers with Co-Occurring Substance Use and Mental Health Disorders (2000), this publication is now available as a downloadable PDF and replicates the content included in the new BHMEDS-R3 app now available in the Apple App Store and Google Play.  Back by popular demand, this 10th Edition publication is acclaimed for its accessibility as an educational reference for addiction professionals, patients, and families. Educators and addiction counselor training programs across the United States have asked that we continue to update and publish a downloadable publication to reflect the same credible and up-to-date information included in the BHMEDS-R3 app. We attempt to update the BHMEDS-R3 app content annually and publish an updated publication biannually.    Medications are organized in 11 sections: Alcohol Use Disorder Treatment Antianxiety Medications Antidepressant Medications Antimanic/Mood Stabilizer Medications Antipsychotics/Neuroleptics Hypnotics (Sleep Aids) Medications Induced Symptoms Treatment Narcotic and Opioid Medications Opioid Use Disorder Treatment Stimulant Medications Tobacco   Each section includes the following topics for the different medication types: Generic and Brand Name Medications: includes both approved FDA approved and “off label” medications.  Purpose: Describes typical uses of medications, including specific symptoms treated and positive treatment response expected.  Dose & Frequency: Discusses when and how medications are administered.  Side Effects: Discusses potential side effects, and methods for monitoring side effects.  Emergency Conditions: Includes risks associated with overdose, withdrawal or other medications’ reactions. Misuse Potential: Elaborates upon those medications with risk factors related to misuse and/or development of physical dependence.  Cautions: Describes general guidance on risks associated with taking medications    IMPORTANT NOTES ACROSS MEDICATION TYPES Name brand medications have a limited patent. When the patent expires, the medication may be made as a generic. The generic name of a medication is the actual name of the medication and never changes. A generic medication may be made by many different manufacturers and can make several forms of a single medication with only slight variations in color, size, or shape.  

According to the 2019 National Survey on Drug Use and Health, almost 10% of people aged 12 or older in Region 8 (Colorado, Montana, North Dakota, South Dakota, Utah, and Wyoming) had a substance use disorder in the past year, which is higher than the national average. In addition, data from this survey show that 403,000 people in the Region had an illicit drug use disorder, with stimulants, opioids, and cannabis named as three of the major illicit drugs used. Certainly, stimulant use (especially methamphetamine) rates are increasing nationally as well as in Region 8. A recent study by Jones, Compton, and Mustaquim (2020) found that 1.6 million adults (over 18) reported past-year use of methamphetamine; over a quarter reported using methamphetamine on more than 200 days; over half had a methamphetamine use disorder; and over 1/5 had injected methamphetamine. In response to these stimulant use trends, representatives from the regional Addiction Technology Transfer Centers (ATTCs), led by the ATTC Network Coordinating Office, created a day-long curriculum titled <i> Stimulants and their Impact on Brain and Behavior: Best Practices and Approaches for Effective Treatment and Recovery. Due to the Public Health Emergency (PHE), this day-long curriculum was re-packaged into a three-part webinar series by the ATTC Stimulant Workgroup. The MPATTC is pleased to sponsor the following events:   • Part 1: Stimulants: What Are They and Who Uses Them?, March 9, 2021 • Part 2: Impact of Stimulant Use on the Brain and Body, March 16, 2021 • Part 3: Effective Treatment Approaches and Recovery Supports, March 23, 2021

Crystal methamphetamine use is growing increasingly common among men who have sex with men (MSM) in the northeastern U.S. and is an important public health concern. This webinar, presented by Adam Viera, PhD student (Yale University), shares preliminary themes emerging from a qualitative study of MSM who use crystal methamphetamine. These themes present important lessons for treatment organizations looking to address crystal meth use among MSM. Download slides | Watch recording Webinar category: Specific populations

Pacific Behavioral Health Collaborating Council (PBHCC) IC&RC Alcohol and Drug Counselor (ADC) Academy Curriculum Developed by the Pacific Southwest Addiction Technology Transfer Center and UCLA Integrated Substance Abuse Programs The IC&RC Alcohol and Drug Counselor (ADC) Academy curriculum is a weeklong training designed to prepare individuals based in the six U.S.-affiliated Pacific Jurisdictions to successfully pass the IC&RC ADC certification exam. The duration of the ADC Academy is forty hours of content spread across five full days of training. Funding for the development of the ADC Academy was provided by the Pacific Behavioral Health Collaborating Council (PBHCC). The curriculum is broken into five modules/days, which include: • Day 1: Introduction to the IC&RC ADC Performance Domains and Review of Psychoactive Drugs • Day 2: Core Competencies of Addiction Counselors – Knowledge and Skill Acquisition of Screening, Intake, Orientation, Assessment, Treatment Planning, and Counseling • Day 3: Core Competencies of Addiction Counselors – Knowledge and Skill Acquisition of Case Management, Crisis Intervention, Client and Family Education, Referral, Report and Record Keeping, and Consultation • Day 4: Core Competencies of Addiction Counselors – Prevention and Treatment of HIV/AIDS and Sexually Transmitted Infections • Day 5: Course Review and Test-Taking Strategies To view and download the IC&RC ADC Academy Curriculum, please visit: http://uclaisap.org/slides/icrc-adc-academy-curriculum.html Acknowledgements: This training was developed by Dr. Thomas E. Freese, PhD (Director of Training of UCLA ISAP and Director of the Pacific Southwest ATTC), Alex R. Ngiraingas, MEd, CSAC II, ICADC, ICPS, and Dr. Christopher C. C. Rocchio, PhD, LCSW, CSAC, ICADC (Clinical Specialist, UCLA) in August of 2018 under contract number 2018-002 by the University of California Los Angeles, Integrated Substance Abuse Programs (UCLA ISAP) and the Pacific Southwest Addiction Technology Center (PSATTC) for the Pacific Behavioral Health Collaborating Council (PBHCC). Additional resource provided by SAMHSA, grant number UR1TI080211. *All PowerPoint presentations and trainer guides are 508 compliant.